首页> 外文OA文献 >The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head.
【2h】

The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head.

机译:注射用硫酸钙/磷酸钙生物陶瓷在治疗股骨头坏死中的用途。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of our study is to describe the rationale, the surgical technique and the early clinical and radiographic results of the treatment of patients with early stage osteonecrosis of the femoral head (ONFH) by performing: core decompression, injection of autologous bone marrow concentrate and the use of a new composite injectable bone substitute (PRO-DENSE(®)), as a mechanical supplementation associated with decompression.\udMETHODS:\ud\udThe study included 37 hips (31 patients, 14 females, 17 males; mean age 43.9 years, range 24-56 years) with stages IC-IIIA ONFH. The outcome was determined by the changes in the Harris hip score (HHS), by progression in radiographic stages and by the need for hip replacement. The mean follow-up was 20.6 months (range 12-32 months).\udRESULTS:\ud\udAt final follow-up the mean HHS increased from 68 points pre-operatively to 86 points post-operatively. The radiological results showed that 29 hips (78.4 %) improved or had no further collapse. The overall clinical success rate of the procedure was 86.5 %, with three conversions to THA, and a failure rate of only 3.3 % in the pre-collapse group.\udCONCLUSIONS:\ud\udWe are encouraged by these early results using core decompression, injection of the autologous bone marrow concentrate and backfilling the defect with an injectable bioceramic for the treatment of early stages of ONFH; as far as a conclusion can be drawn from the current data, this treatment seems to relieve hip pain and prevent the progression of ONFH in the majority of the cases.
机译:我们的研究目的是通过以下方法描述股骨头早期骨坏死(ONFH)患者的治疗原理,手术技术以及早期的临床和放射学结果,包括:核心减压,自体骨髓浓缩液注射和使用新型复合材料可注射骨替代物(PRO-DENSE(®))作为与减压相关的机械补充剂。\ ud方法:\ ud \ ud这项研究包括37髋(31例患者,14例女性,17例男性;平均年龄43.9)年,范围为24-56岁),阶段为IC-IIIA ONFH。结局取决于哈里斯髋关节评分(HHS)的变化,影像学阶段的进展以及是否需要髋关节置换。平均随访时间为20.6个月(范围为12-32个月)。\ ud结果:\ ud \ ud在最终随访中,平均HHS从术前的68分提高到术后的86分。放射学结果显示29髋(78.4%)改善或没有进一步塌陷。该过程的整体临床成功率为86.5%,其中有3次转换为THA,而崩溃前组的失败率仅为3.3%。\ ud结论:\ ud \ ud我们对采用核心减压的早期结果感到鼓舞,注射自体骨髓浓缩液,并用可注射的生物陶瓷回填缺损,以治疗ONFH的早期阶段;从目前的数据可以得出的结论来看,这种治疗在大多数情况下似乎可以缓解髋部疼痛并防止ONFH的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号